跳至主要内容
临床试验/NCT06423508
NCT06423508招募中不适用

PRObing The Efficacy of Commercial Stage Storage Buffers and Evaluating Gut Metaproteome Variability Between Individuals

University of Vienna1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2024年12月3日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
52
试验地点
1
主要终点
Eggerthella abundance

研究概览

简要总结

The study aims to assess the effectiveness of various commercial and non-hazardous buffers for the storage of human gut fecal samples over time. This evaluation will be conducted by comparing the performance of these buffers against directly frozen samples using metaproteomic analysis. The study is motivated by the need for standardized protocols for sample preservation in metaproteomic research, particularly focusing on protein preservation in fecal samples. By investigating proteomic, taxonomic, and functional identifications, the research seeks to provide insights into the reliability of these buffers as storage solutions. Additionally, the study plans to explore inter- and intra-individual variabilities at the proteome level by periodically collecting fecal samples from volunteers, complementing existing knowledge in metaproteomics. Overall, the study addresses a critical gap in the field and has the potential to enhance reproducibility and comparability across metaproteomic studies

详细描述

A. Introduction:

Metaproteomics studies the entire protein complement of a microbial community and offers insight into intricate ecosystems like the gut microbiome. Metaproteomics allows researchers to delve deep into gut microbiomes, providing insights into these microbial inhabitants, abundance and functional activities. This knowledge has been instrumental in elucidating the mechanisms underlying various diseases, such as inflammatory bowel disease, and obesity. Researchers can develop targeted strategies for personalized medicine and precision healthcare based on the underlying biology by identifying key protein signatures.

In gut microbiome studies, standardized sample collection and preservation are particularly crucial to preserve the integrity of the microbial community and its proteome. Indeed, to obtain reliable results it must be considered the susceptibility to environmental influences like temperature and oxygen amount. For gut microbiome metaproteomic studies, non-invasive or minimally invasive methods are preferred to minimize disruption, or contamination, and preserve the native microbial composition and protein profiles. Also, the sample handling and storage strategies affect the degradation of proteins and the microbial population stability. For this reason, immediate freezing, or preservation at low temperatures (e.g., -80°C) is often recommended to maintain sample integrity until analysis. However, using a cold chain for storage and transportation is not compatible with an on-site sampling strategy that is necessary for large-scale and delocalized studies. Moreover, it is less ideal, more expensive, and logistically tedious than potential room temperature options.

Furthermore, present knowledge of the fecal sample collection/preservation methods is based on preserving nucleic acids or metabolites during the transportation to the laboratory for analysis. However, protein preservation requires different strategies and studies are scarce and rely on adopting the devices or reagents used in the case of nucleic acids or metabolites analysis. Thus, tailored, and standardized protocols together with metadata collection are essential for ensuring reproducibility and comparability across metaproteomic studies.

The present study aims to evaluate the fitness of several commercial and non-hazardous buffers for the storage of human gut fecal samples over time. Fecal samples will be stored in five different buffers and will be benchmarked with directly frozen samples. Using metaproteomics the investigators will compare the proteomic, taxonomic, and functional identifications to understand the potential of these buffers as a reliable storage solution for human feces. This research is unique and to the best of our knowledge, no similar study has addressed this demanding question.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • agreeing to participate after signing the informed consent form and
  • being 18-70 years old.

排除标准

  • take antibiotics during the previous 1 month
  • had undergone gastrointestinal surgery

结局指标

主要结局

Eggerthella abundance

时间窗: From enrollment to the end of treatment at 4 weeks

Eggerthella abundance will be checked in to the Metaproteomic profile of each fecal samples and inter/intra-individual variability will be assessed

次要结局

  • Body Mass Index (BMI)(From enrollment to the end of treatment at 4 weeks)
  • Antibiotic use(From enrollment to the end of treatment at 4 weeks)
  • Bristrol Stool Form Scale (BSFS)(From enrollment to the end of treatment at 4 weeks)
  • Age(From enrollment to the end of treatment at 4 weeks)
  • Sex(From enrollment to the end of treatment at 4 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Giacomo Carta

Postdoc

University of Vienna

研究点 (1)

Loading locations...

相似试验